title: The non-antidepressant effects of citalopram: a clinician's perspective.
abstract: The authors present an overview of the most often discussed questions concerning citalopram, i.e. its proven effect on the QT interval and related dose reductions. They discuss citalopram's antiplatelet effect including the most recent data and draw attention to serotonin syndrome as its incidence is still underestimated. They go on to discuss hyponatremia pointing out that this condition may develop even in those taking low doses of citalopram. Finally, the authors provide a brief overview of the latest findings on osteoporosis and the serotonergic mechanism inducing it in individuals treated with a selective serotonin reuptake inhibitor.
authors.affiliation: Department of Geriatrics, 1st Faculty of Medicine, Charles University in Prague,, Czech Republic.
authors.forename: Tomas
authors.initials: T
authors.lastname: Richter
authors.affiliation: St. Elizabeth University of Health and Social Work, Bratislava, Slovakia, St. J.N. Neumann Institute, Pribram, Czech Republic.
authors.forename: Zoltan
authors.initials: Z
authors.lastname: Paluch
authors.affiliation: Institute for Postgraduate Medical Education, Charles University, Prague, Czech Republic.
authors.forename: Stefan
authors.initials: S
authors.lastname: Alusik
mesh_terms: D015283:Citalopram / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced*; D010024:Osteoporosis / Q000139:chemically induced*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D029597:Romano-Ward Syndrome / Q000139:chemically induced*; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D020230:Serotonin Syndrome / Q000139:chemically induced*
chemical_list: D010975:Platelet Aggregation Inhibitors; D012702:Serotonin Antagonists; D015283:Citalopram